Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".
Dong-A University Medical Center, Busan, South Korea.
Sung-Hyun
SH
Kim
Seoul St. Mary's Hospital, Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea dwkim@catholic.ac.kr.
Dong-Wook
DW
Kim
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl
chronic myeloid leukemia; radotinib